格隆汇8月26日丨清晰医疗(01406.HK)公告，卢子康已提出辞任公司执行董事一职，自2025年9月1日起 生效，以便将更多时间投放于其他个人及业务发展。 ...

智通财经APP讯，清晰医疗(01406)发布公告，卢子康先生已提出辞任公司执行董事一职，自2025年9月1 日起生效，以便将更多时间投放于其他个人及业务发展。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CLARITY MEDICAL GROUP HOLDING LIMITED 清晰醫療集團控股有限公司 非執行董事兼主席 胡定旭 清晰醫療集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）宣佈，盧子康先生（「盧先生」）已提出辭任本公司執行董 事一職，自二零二五年九月一日起生效，以便將更多時間投放於其他個人及業務 發展。 盧先生已確認，彼與董事會並無意見分歧，亦無有關彼辭任的其他事宜須提請本 公司股東及香港聯合交易所有限公司垂注。 董事會謹此衷心感謝盧先生於任職期間為本公司作出的寶貴貢獻。 承董事會命 清晰醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1406） 執行董事辭任 於本公告日期，董事會成員包括執行董事蔣波先生、許勇先生及盧子康先生；主 席兼非執行董事胡定旭先生；以及獨立非執行董事鄭宇凌女士、王燦先生及慈瑩 女士。 香港，二零二五年 ...

Group 1 - Prism Horizons Partners Limited increased its stake in Clear Medical (01406) by acquiring 78,125,196 shares at a price of HKD 0.8 per share, totaling approximately HKD 62.5 million [1] - Following the transaction, Prism Horizons Partners Limited's total shareholding in Clear Medical is approximately 78,125,196 shares, representing a 14.57% ownership stake [1] - The transaction involves other related parties, specifically WANG MEIYAN [1]

本交易涉及其他关联方：WANG MEIYAN。 智通财经APP获悉，香港联交所最新资料显示，8月15日，Prism Horizons Partners Limited增持清晰医疗 (01406)7812.5196万股，每股作价0.8港元，总金额约为6250.02万港元。增持后最新持股数目约为 7812.52万股，最新持股比例为14.57%。 ...

Core Viewpoint - The article discusses the transformation of the ophthalmology sector in Hong Kong, highlighting the challenges and opportunities presented by technological advancements and regional integration within the Greater Bay Area. Clear Medical (01406.HK) is presented as a case study of a company that has faced significant operational challenges but is now on a path to recovery under new management led by Jiang Bo, who emphasizes the importance of technology and effective resource allocation in driving growth [2][4]. Group 1: Company Overview - Clear Medical faced continuous losses and cash flow issues after its 2022 IPO, primarily due to over-reliance on individual doctors and aggressive expansion strategies [2][4]. - In mid-2024, a new management team led by Jiang Bo implemented strategic changes, including closing underperforming locations and enhancing cash flow management, which helped the company begin to recover [2][4][6]. Group 2: Strategic Initiatives - The management's initial focus was on "stop the bleeding" and "counting the money," emphasizing the need for effective resource allocation to restore the company's financial health [6]. - Key actions included recovering loans from departed doctors and shutting down a high-rent center in Tsim Sha Tsui, which significantly reduced ongoing losses [7]. - The company expanded its insurance channel revenue from 0.7% to 6.3%, diversifying income sources and reducing reliance on individual doctors [7]. Group 3: Technological Integration - Clear Medical aims to leverage its position in introducing cutting-edge ophthalmic technologies, maintaining a competitive edge in Hong Kong's healthcare market [8][15]. - The company is actively collaborating with leading AI teams to integrate AI systems into clinical practices, positioning itself as a pioneer in this area within Hong Kong [12]. Group 4: Market Trends and Future Outlook - The ophthalmology sector is witnessing new demands driven by rising myopia rates among youth and an aging population, alongside technological innovations that are reshaping the industry [17]. - Clear Medical's strategy includes focusing on technological innovation to meet emerging needs and optimizing service experiences to blur the lines between healthcare and consumer services [17]. - The management is committed to ensuring compliance with regulatory requirements while working towards the company's relisting, emphasizing the importance of governance and transparency [18][19].

Group 1 - The article discusses the transformation of Clear Medical (01406.HK) under the leadership of Jiang Bo, who aims to turn the company around from continuous losses to profitability through strategic reforms and technological advancements [2][3][20] - Jiang Bo's management team, composed of professionals from diverse backgrounds, focuses on resource optimization and effective cash flow management to restore the company's financial health [3][7] - The company has implemented significant changes, including closing underperforming locations and enhancing revenue streams through insurance partnerships, resulting in a substantial reduction in cash outflow and EBITDA losses [6][19] Group 2 - The article highlights the ongoing transformation in the Hong Kong ophthalmology market, driven by technological advancements and regional integration, presenting both challenges and opportunities for companies like Clear Medical [2][8] - Clear Medical is positioned to leverage its technological capabilities and market potential, aiming to become a leader in the ophthalmology sector by introducing innovative solutions and collaborating with mainland institutions [12][18] - The company is adopting a "dual-wheel drive" technology strategy, focusing on both importing advanced technologies and promoting innovative domestic solutions to enhance service accessibility and effectiveness [12][18] Group 3 - Jiang Bo emphasizes that all great companies are fundamentally technology companies, and Clear Medical aims to integrate cutting-edge technologies, such as AI, into its operations to gain a competitive edge [10][11] - The management's approach is influenced by investment principles, focusing on value creation through strategic resource allocation and operational efficiency [15][16] - The company is committed to addressing emerging demands in the ophthalmology field, such as myopia prevention and treatment for age-related eye diseases, while also navigating the blurred lines between healthcare and consumer services [18][19]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 第 1 頁 共 10 頁 v 1.1.1 FF301 致：香港交易及結算所有限公司 公司名稱: 清晰醫療集團控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01406 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 5,000,000,000 | HKD | | 0 ...

Group 1 - The company announced the removal of Dr. Xie Weiyi from the board due to unresolved legal disputes and bankruptcy petitions against him, as well as formal notifications from the Hong Kong government regarding his unpaid debts [1] - The board sought legal advice from Cayman Islands counsel regarding the interpretation of Article 86(4) of the company's articles of association, which pertains to the disqualification of directors who suspend debt repayment or reach settlement agreements with creditors [1] - A board meeting was held on August 1, 2025, where a majority decision was made to revoke Dr. Xie Weiyi's directorship, effective immediately, with two directors opposing the decision due to conflicts of interest [1] Group 2 - Mr. Wang Can, an independent non-executive director, appointed Mr. Jiang Bo, an executive director, as his alternate to vote on resolutions during the board meeting, without extending this appointment to other roles [2]

Core Viewpoint - Clear Medical (01406) announced the removal of Dr. Xie Weiye from the board due to unresolved legal disputes and bankruptcy petitions, as well as formal notifications from the Hong Kong government regarding unpaid debts [1] Group 1: Board Decisions - The board of directors convened on August 1, 2025, to consider the removal of Dr. Xie Weiye's directorship based on Article 86(4) of the company's articles of association [1] - A majority vote resulted in the immediate removal of Dr. Xie Weiye from the board, with Ms. Zheng Yuling and Mr. Lu Zikang voting against the decision [1] - Dr. Xie Weiye was required to abstain from voting due to his significant interest in the matter [1] Group 2: Legal and Governance Considerations - The board sought legal advice from Cayman Islands counsel regarding the interpretation of Article 86(4) related to the suspension of debt repayment or reaching settlement agreements with creditors [1] - The company's Hong Kong legal advisors recommended that the board consider all facts when applying Article 86(4) to Dr. Xie Weiye [1] - The board acknowledged its fiduciary duties in maintaining corporate governance standards [1] Group 3: Proxy Voting - Mr. Wang Can, an independent non-executive director, appointed Mr. Jiang Bo, an executive director, as his proxy to vote on the resolutions during the board meeting due to his business trip [2]